UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 711, 2018

Nexeon Medsystems Inc

(Exact name of registrant as specified in its charter)

Nevada		000-55655		81-0756622
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1910 Pacific Avenue, Suite 20000

Dallas, Texas 75201

(Address of principal executive offices) (zip code)

844-919-9990

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~ITEM 1~~Item 7.01 ~~Entry~~Regulation ~~Into~~FD ~~a Material Definitive Agreement~~Disclosure.

~~On December 7, 2018,~~ Nexeon Medsystems Inc, ~~a Nevada corporation~~ (the “Company”) ~~entered~~has ~~into~~made available an ~~employment~~updated ~~agreement~~presentation ~~with~~about its ~~Chief~~ ~~Executive Officer and Chairman~~business, ~~William Rosellini (the “Employment Agreement”) pursuant to which Mr. Rosellini shall continue to serve as the Company’s Chief Executive Officer and Chairman for~~ a ~~period~~copy of ~~two~~which ~~years~~is ~~(the~~filed ~~“Term”)~~as inExhibit ~~consideration for an annual base salary of One Dollar ($1~~99.~~00).~~1 ~~On the second and subsequent anniversary dates of the Term, the Employment Agreement will be automatically extended for an additional year unless, not later than 90 calendar days prior~~ to ~~such~~this ~~anniversary~~Current ~~date,~~Report the Company shall notify Mr. Rosellini of its intent to not extend the Term. Pursuant to the Employment Agreement, the Company may terminate Mr. Rosellini’s employment for Cause (as such term is defined in the Employment Agreement) at any time or without Cause on ~~thirty~~Form ~~(30) days’~~8-K ~~written notice. If Mr. Rosellini’s employment is terminated without Cause or in connection with a Change in Control~~ (~~as defined in~~ the ~~Employment Agreement~~“Report”), ~~Mr. Rosellini shall be entitled to a severance payment equal to a scaling percentage of his highest base salary~~ and ~~targeted~~is ~~bonus~~hereby orincorporated ~~incentive~~by ~~compensation, if any~~reference. ~~Mr. Rosellini shall have the right to terminate his employment at any time with Good Reason (as defined in the Employment Agreement) upon ninety (90) days’ written notice.~~

The information ~~Employment~~contained ~~Agreement~~in ~~provides~~the ~~for~~presentation ~~customary~~is ~~non-solicitation,~~summary information that should be considered in the context of the Company’s ~~confidentiality~~filings with the Securities and ~~invention~~Exchange ~~assignment~~Commission ~~clauses~~and other public announcements the Company may make by press release or otherwise from time to time. The presentation speaks as of the date of this Report. While the Company may elect to update the presentation in the future to reflect events and circumstances occurring or existing after the date of this Report, the Company specifically disclaims any obligation to do so.

The presentation ~~foregoing~~contains ~~description~~forward-looking ofstatements, ~~the Employment Agreement is not complete~~ and isas ~~qualified~~a inresult, ~~its~~investors ~~entirety~~should bynot ~~reference~~place toundue ~~the~~reliance ~~full~~on ~~text~~these ~~of the form of Employment Agreement, a copy of which is~~forward-looking ~~filed as Exhibit 10~~statements.~~1 to this Report and incorporated by reference herein.~~

~~Item~~The information ~~5.02~~set ~~Departure~~forth ofin ~~Certain~~this ~~Officers;~~Report, ~~Election~~including without limitation the presentation, is not deemed “filed” for purposes of ~~Directors;~~Section ~~Appointment~~18 of ~~Certain~~the ~~Officers;~~Securities ~~Compensatory~~Exchange ~~Arrangements~~Act of ~~Certain~~1934, ~~Officers~~as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

~~The information in~~ Item 1 9.01 isFinancial ~~hereby incorporated~~Statements byand ~~reference to this Item 3~~Exhibits.~~03.~~

~~Item 9.01 Financial Statements and~~ (d) Exhibits.

~~(d)~~The exhibits ~~Exhibits~~listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

Exhibit No.		Description

99.1		Corporate Presentation

Exhibit No.		Description
10.1		Employment Agreement between Nexeon Medsystems Inc and William Rosellini dated December 7, 2018

1SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEXEON MEDSYSTEMS INC

Dated: December 11, 2018	/s/ William Rosellini
	William Rosellini
	Chairman and Chief Executive Officer

	NEXEON MEDSYSTEMS INC
Dated: December 7, 2018	/s/ Christopher Miller
	Christopher Miller
	Chief Financial Officer

Filing Compare · NEXEON MEDSYSTEMS INC